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Background: Radiation exerts direct antitumor effects and is widely used in clinics, but the efficacy is
severely compromised by tumor resistance. Therefore uncovering the mechanism of radioresistance might
promote the development of new strategies to overcome radioresistance by manipulating activity of the
key molecules.
Methods: Immunohistochemistry were used to find whether mTOR were over-activated in radioresistant
patients’ biopsies. Then Western blot, real-time PCR and transfection were used to find whether
radiotherapy regulates the expression and activity of mTOR by modulating its targeting microRNA in
human pancreatic cancer cell lines PANC-1, Capan-2 and BxPC-3. Finally efficacy of radiation combined
with mTOR dual inhibitor AZD8055 was assessed in vitro and in vivo.
Results: Ionizing radiation promoted mTOR expression and activation in pancreatic cancer cells through reducing
miR-99b expression, which negatively regulated mTOR. Novel mTOR inhibitor, AZD8055 (10 nM, 100 nM, 500 nM)
synergistically promoted radiation (0–10 Gy) induced cell growth inhibition and apoptosis. In human pancreatic cancer
xenografts, fractionated radiation combined with AZD8055 treatment further increased the anti-tumor effect, the
tumor volume was shrinked to 278 mm3 after combination treatment for 3 weeks compared with single radiation
(678 mm3) or AZD8055 (708 mm3) treatment (P < 0.01).
Conclusions: Our data provide a rationale for overcoming radio-resistance by combined with mTOR inhibitor
AZD8055 in pancreatic cancer therapy.
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Pancreatic cancer is the fourth leading cause of cancer
death, and is amongst the deadliest of human cancers.
Only 10-15% patients undergo surgery due to late diagno-
sis, therefore radiotherapy becomes the major way in the
treatment of pancreatic cancers in clinics, either alone or
in combination with chemotherapy [1]. Local control of
tumor growth is partly achieved by radiation-induced cell
death as a result of damage to cell membranes and DNA
[2,3]. However, the efficacy of radiotherapy remains* Correspondence: xue_xiaochang@yahoo.com; luzfliuq@fmmu.edu.cn
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reproduction in any medium, provided the orlimited due to intense tumor resistance. The molecular
mechanisms underlying radiation resistance of pancreatic
cancer are not fully understood [4].
The mammalian target of rapamycin (mTOR), a well-
known serine/threonine kinase, is identified as a down-
stream target of PI3K/Akt survival pathway and functions
as a central regulator of cell growth, proliferation and
survival [5,6]. Accumulating evidence demonstrated
that mTOR was dysregulated in various cancers, its
over-expression and over-activation contribute to can-
cer progression and drug-resistance [7,8]. As a result,
mTOR inhibitors represent a promising therapeutic ap-
proach for cancer and solid tumors [9,10].
The first generation mTOR inhibitors, like rapamycin
and its analogs everolimus (RAD001), temsirolimus (CCI-
779) and ridaforolimus (AP23573), have been developed
as cancer therapeutic agents [10,11]. However, they are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect due to the feedback of AKT activation via up-
regulating insulin-like growth factor-1 (IGF-1) [12]. AZD-
8055, a novel ATP-competitive inhibitor of mTOR kinases,
besides preventing feedback to AKT, potently showed ex-
cellent selectivity (about 1,000 fold) against all class I PI3K
isoforms and other members of the PI3K-like kinase family.
AZD8055 is currently tested in phase I clinical trials as an
anti-tumor drug [13,14]. Prior studies reported that com-
bination of mTOR inhibitor RAD001 with radiotherapy
can delay solid tumor growth in vitro and in vivo due to
synergistic anti-angiogenic and anti-vascular effects [15],
but the detail mechanisms remain poorly defined. Here, we
wonder whether mTOR inhibitor AZD8055 can also amp-
lify the radiotherapeutic effects in pancreatic cancers.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs which play important roles in gene regulation by
targeting mRNA in a sequence-specific manner, and their
dysregulations are a common feature in tumorigenesis and
drug-resistance [16,17]. Numerous studies have shown
that miR-99b, miR-100, miR-199a-3p, miR-451, miR-144
and miR-101 can directly or indirectly mediate mTOR ex-
pression [18-23], and reduction of these miRNAs was
connected with the elevated levels of mTOR in prostate
cancer and endometrial carcinoma [18,24]. However, it is
still not clear whether these miRNAs can be regulated by
radiation and be connected with aberrant mTOR activa-
tion in pancreatic cancer.
In this study, we identified that mTOR is positively
regulated by radiation in both human pancreatic biopsy
specimens and cell lines, and this mTOR upregulation is
promoted by radiation induced miR-99b downregu-
lation. We further provided evidence that dual mTOR
inhibitor AZD8055 significantly reversed the aberrant
mTOR activation, consequently sensitized pancreatic can-
cer cell lines and xenografts to radiotherapy. Thus, our
data provide a rationale for overcoming radio-resistance
by combined with mTOR inhibitor AZD8055 in pancre-
atic cancer therapy.
Results
mTOR was upregulated in pancreatic cancer patients
subjected to radiotherapy
Although some signaling cascades such as Ras/PI3K/
PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 have been
implicated in regulation of tumor radioresistance, the de-
tail mechanism is still largely unknown. To determine the
key factors that influence the response of pancreatic can-
cer patients to radiotherapy, tumor biopsies from patients
subjected to radiotherapy were examined. Several proteins,
including mTOR, were differentially expressed in pre- or
post-radiotherapy specimens. As shown in Figure 1, the
expression of mTOR in post-radiotherapy samples was sig-
nificantly higher than that in pre-treatment specimens byimmunohistochemical analysis (Figure 1A). Western blot
further confirmed that the level of active phosphorylated
S6 (p-S6) as the key downstream molecule of mTOR sig-
naling pathway was consistently up-regulated in the sam-
ples upon stimulation with radiation (Figure 1B). These
data indicated that radiotherapy could induce the over-
expression and over-activation of mTOR pathway in pan-
creatic cancer tissues and which may relate with the tumor
resistance to radiotherapy.
Ionizing radiation upregulates mTOR in pancreatic cancer
cells at both transcriptional and protein levels
To identify whether ionizing radiation modulates the ex-
pression and activity of mTOR in human pancreatic can-
cer, PANC-1 cells were cultured in normal condition
and treated with increasing doses of radiation for 1 h. As
shown in Figure 2A, radiation induced a dose-dependent
increase of both mTOR and p-mTOR at doses from
0 Gy to 10 Gy. To confirm this, mTOR levels were also
examined in other two pancreatic cell lines, Capan-2
and BxPC-3, with radiation treatment at 5 Gy and the
similar results were obtained (Figure 2B). Furthermore,
the mRNA level of mTOR was detected and results
showed that mTOR transcript was up-regulated by radi-
ation in PANC-1 cells and the peak value appeared at
5 Gy by 4.36 fold (Figure 2C), similar data were ob-
tained in BxPC-3 and Capan-2 cells (data not shown).
Meanwhile, Bcl-2, Bcl-XL and Mcl-1 as principal mem-
bers of apoptosis family showed no big difference before
and after radiation treatment (Figure 2D). Collectively,
ionizing radiation significantly induces mTOR expres-
sion and activation at mRNA as well as protein levels,
which possibly contribute to radioresistance in pancre-
atic cancer.
mTOR is a critical factor in pancreatic
cancer radioresistance
To further verify whether mTOR is a direct factor that is
involved in radioresistance of pancreatic cancer, PANC-1
irradiation-resistant cell line (PANC-1-RR) was generated
and colony formation assay was used to confirm the
radioresistance ability of PANC-1-RR (Figure 3A). Intri-
guingly, higher levels of mTOR and p-mTOR were ob-
served in PANC-1-RR cells as compared with PANC-1-P
cells (Figure 3B). To further test that mTOR is indispens-
able in the radioresistance,mTOR specific shRNA was
transfected into PANC-1 cells. After transfection, cells
were treated with radiation for 48 h, results revealed that
endogenous mTOR in PANC-1 cells was remarkably
downregulated (Figure 3C) and PANC-1 cells were more
sensitive to radiation in mTOR shRNA transfection group
as compared with the control shRNA group (Figure 3D).
All these data collectively demonstrate that radiation in-
duced mTOR expression and activation contributes to
Figure 1 mTOR expression and activation in pancreatic cancer patients before and after radiotherapy. (A) Examination of mTOR in the
tissue sections from pancreatic cancer patients pre- or post-radiotherapies by Immunohistochemistry (200 × magnification). (B) Western blot
analysis of S6 and p-S6 protein in pre-radiotherapy tumors (N) and post-radiotherapy tumors (T). Actin was used as a loading control.
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fectively overcomes the radioresistance of pancreatic can-
cer cells.
Downregulation of miR-99b, a key mediator of mTOR
kinase, contributes to radiation induced mTOR upregulation
It is well known that miRNAs widely participate in gene
expression regulation and play critical roles in various phys-
iological and pathological processes. To identify whether
miRNAs were involved in radiation induced mTOR aber-
rant expression and activation, several miRNAs which
targeted mTOR kinase including miR-101, miR-144, miR-
100, miR-451, miR-199a and miR-99b were tested before
and after radiation treatment. We found that miR-99b
decreased most significantly by 2.7 fold after treatment
with radiation at 5 Gy (Figure 4A). Although it was re-
ported that mTOR was a target gene of miR-99b, we con-
firmed this with the luciferase reporter assay system and
results showed that miR-99b can specifically recognize the
seed sequence located in the 3′UTR of mTOR (Additional
file 1: Figure S1). To further test whether miR-99b is able
to regulate the expression of endogenous mTOR, miR-99bprecursor or inhibitor was transfected into PANC-1 cells
with or without radiation. Results showed that radiation
dramatically upregulated mTOR expression in all these
three groups compared with parallel samples without radi-
ation, whereas miR-99b precursor suppressed and miR-99b
inhibitor upregulated mTOR under the basal and radiation
conditions when compared with control group (Figure 4B).
All these findings disclose that reduction of miR-99b
contributed to the upregulation of mTOR kinase in pancre-
atic cells and putatively influenced the cell sensitivity to
radiotherapy.
In order to validate whether miR-99b could affect the
cell sensitivity towards radiotherapy, PANC-1 cells were
treated with radiation before and after miR99b precur-
sor/inhibitor transfection. As shown in Figure 4C and D,
cell growth and proliferation were significantly inhibited
after downregulation of mTOR expression by miR-99b
precursor whereas cells were more resistant to radiation
after upregulation of mTOR by miR-99b inhibitor. All
these data suggested that downregulation of miR-99b
might induce cell resistance to ionizing radiation via en-
hanced mTOR expression.
Figure 2 Radiation induces mTOR phosphorylation in association with mTOR upregulation on mRNA and protein levels. (A) PANC-1
cells were treated with indicated doses of IR for 1 h. mTOR, p-mTOR, AKT, p-AKT or Bcl-2 family members were analyzed by Western blot, and the
intensity of mTOR expression was quantified with ImageJ software. (B) The above proteins were analyzed in PANC-1, Capan-2 and BxPC-3 cell
lines after treated with radiation at 5 Gy. (C) Relatively fold changes of mTOR mRNA were analyzed by RT-PCR in PANC-1 cells. (D) Relatively fold
changes of mTOR, Bcl-2, Bcl-XL and Mcl-1 mRNA were analyzed by RT-PCR. GAPDH were used as a blank control. Data are representative of three
experiments. Error bars represent as mean± S.D. **, P < 0.01 vs. control.
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pancreatic cancer cells to ionizing radiation
As we know, AZD8055 is a novel and effective ATP-
competitive inhibitor of mTOR kinase activity (Figure 5A).It inhibits the phosphorylation of mTORC1 substrates
S6K and 4E-BP1 as well as mTORC2 substrate AKT and
downstream proteins. According to our above findings, we
supposed that inhibition of mTORC1/2 phosphorylation
Figure 3 mTOR play a critical role in pancreatic cancer radioresistance. (A) Parental PANC-1 (PANC-1-P) and radiation resistant
PANC-1 cells (PANC-1-RR) were treated with increasing doses of radiation and cultured for 10 days, cell growth was analyzed by colony
formation assay and the data were statistically analyzed. The experiment was repeated three times and the number of colonies was
presented as mean ± SD. *, P < 0.05 vs. control and **, P < 0.01 vs. control and PANC-1-RR cells. (B) Expression and/or phosphorylation
of mTOR, Akt, 4EBP1, Bcl-2, Bcl-XL and Mcl-1 in PANC-1-P and PANC-1-RR cells were analyzed by Western blot. (C) mTOR shRNA and
control were transfected into PANC-1 cells and mTOR expression was analyzed by Western blot. (D) Cells were transfected and then
treated with increasing doses of radiation for 48 h, cell viability was analyzed by SRB assay. Error bars represent ± S.D. *, P < 0.05 vs.
vector-only control and **, P < 0.01 vs. vector-only control.
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radiation. To confirm this hypothesis, PANC-1 cells were
treated with radiation in the absence or presence of
AZD8055, the results disclosed that all of the doses of
AZD8055 combined with radiation showed a synergetic in-
hibition of cell growth. As shown in Figure 5B, radiation
(0 Gy, 1 Gy, 2.5 Gy, 5 Gy, 10 Gy) or AZD8055 (10 nM, 100
nM, 500 nM) single treatment caused less than 40% cell
growth inhibition, whereas the combination caused more
than 80%. Colony formation assay also showed that almost
all the PANC-1 cells were eliminated by the combination
treatment compared to radiation or AZD8055 treated
alone (Figure 5C). The similar data were achieved with the
other two pancreatic cancer cell lines (data not shown).
Altogether, our data suggest that blockade of mTOR signal
pathway by AZD8055 could reverse radioresistance and
sensitize pancreatic cancer cells to ionizing radiation.AZD8055 enhances radiation induced cell cycle disruption
and cell apoptosis
To evaluate whether AZD8055 combined with radiation
affects cell cycle distribution, PANC-1 cells were treated
with indicated doses of radiation and/or AZD8055 as de-
scribed previously. We found that AZD8055 or radiation
alone caused a slight accumulation of cells in G0/G1
phases (from 58% to 67% or 77%) and a mild reduction
in S phase (from 18% to 10% or 8%) compared with con-
trol cells, whereas a more extensive cell cycle pertur-
bation was caused by their combined treatment, with an
accumulation of cells in G0-G1 phase (93%), and a sig-
nificant reduction in S phase (3%) (Figure 6A).
Then Annexin V assay was employed to test whether
the combination treatment was accompanied with in-
creased programmed cell death. As shown in Figure 6B,
Radiation or AZD8055 alone merely induced a small
Figure 4 Radiation down-regulates miR-99b which targets mTOR in pancreatic cancer cells. (A) miR-101, miR-144, miR-100, miR-451, miR-199a
and miR-99b were tested by real-time PCR before and after radiotherapy (5 Gy), **, P < 0.01 vs. control. (B) miR-99b precursor or miR-99b inhibitor was
transfected into PANC-1 cells, followed by radiation at 5 Gy, and mTOR expression was analyzed by Western blot using an mTOR antibody. Western
blot bands of mTOR were further quantified by the ImageJ software for calculating the expression of mTOR before and after miR-99b precursor/
inhibitor transfection, **, P < 0.01 vs. control with IR. (C) PANC-1 cells were treated with radiotherapy (5 Gy) before and after miR99b precursor/
inhibitor transfection for 48 h. Cell viability (%) was analyzed by SRB assay. Error bars represent as mean ± SD, **, P < 0.01 vs. control with IR or miR-99b
inhibitor with IR. (D) PANC-1 cells were untreated or treated with radiation (1.5 Gy × 3) before and after miR-99b precursor/inhibitor transfection for
10 days and cell viability was analyzed by colony formation assay. The experiment was repeated three times and the number of colonies was
represented as mean ± SD. **, P < 0.01 vs. control with IR or miR-99b inhibitor with IR.
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Figure 5 AZD8055 blocks radiation-induced mTOR phosphorylation and sensitizes pancreatic cancer cells to radiotherapy. (A) Chemical
structure of mTOR dual inhibitor AZD8055, [5-[2,4-Bis((3S)- 3-methylmorpholin −4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol.
(B) PANC-1 cells were treated with indicated doses of radiation in the absence or presence of AZD8055 for 48 h, Cell growth inhibition was
analyzed by SRB assay. Error bars represent as mean ± SD. *, P < 0.05 vs. control or IR treatment alone and **, P < 0.01 vs. control or IR treatment alone.
(C) PANC-1 cells were treated with radiation or AZD8055, alone or in combination, and cell viability was analyzed by colony formation assay. The
experiment was repeated three times and the number of colonies was presented as mean ± SD. **, P < 0.01 vs. IR or AZD8055 treatment alone.
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5 Gy or 500 nM. Intriguingly, AZD8055 combined with
radiation synergistically induced significant cell apop-
tosis by 48.2%. Our findings indicate that AZD8055 en-
hanced ionizing radiation induced cell apoptotic and cell
cycle arrest.
Suppression of mTOR activation by AZD8055 enhances
antitumor efficacy of radiation in pancreatic
cancer xenografts
Our in vitro studies have proved the principle that radi-
ation combined with AZD8055 could synergistically in-
hibit cell proliferation and induce apoptosis. To evaluate
these effects in vivo, mice bearing subcutaneous PANC-1
xenografts were randomized and treated for three weeks
as described in “Materials and methods”. As indicated in
Figure 7A and B, in mice that received fractionated radi-
ation alone, tumors grew slowly during the early two
weeks, then the growth rate resumed similar to the control
group (P > 0.05), meanwhile in association with high level
of p-mTOR in tumor tissues. Interestingly, more coopera-
tive antitumor effect was observed when AZD8055 wasused in combination with fractionated radiation, with a sig-
nificant reduction of the volumes of the xenografts at the
end of treatment in all of the mice as compared with con-
trol and radiation alone group. In addition, AZD8055 ap-
parently blocked radiation-stimulated mTOR expression
and phosphorylation in tumor tissues (Figure 7B). All the
data collectively demonstrated that blockage of radiation-
induced aberrant mTOR expression and phosphorylation
significantly sensitized pancreatic cancer cells to radiation
and acquired increased anti-tumor activity in vivo.
To evaluate the role of apoptosis in this xenografts
model, TUNEL assay was used to detect the tumor tis-
sues and results showed that inhibition of mTOR path-
way by AZD8055 significantly enhances apoptosis in
pancreatic xenograft tissues (P < 0.01) (Figure 7C).
Discussion
Pancreatic cancer is the most devastating type of cancer,
the 5-year survival rate of patients is less than 5% [25].
Until now, the late diagnosis and persistent resistance to
chemo- and radio-therapy are still the leading problems in
clinics [26]. Although the current standard gemcitabine
Figure 6 Blockade of radiation-induced mTOR phosphorylation by AZD8055 enhances radiation induced cell cycle arrest and
apoptosis. (A) PANC-1 cells were treated with radiation (5 Gy) in the absence or presence of AZD8055 (500 nM) for 24 h, followed by analysis of
cell cycle by flow cytometry. The cells in G0/G1, S and G2/M phases were presented in the percentage. The experiment was repeated three times
and the percentages of cells in G0/G1 and S phases were presented as mean ± SD. (B) Annexin-V/PI cell apoptosis analysis of PANC-1 cells
treated with radiation in the absence or presence of AZD8055 for 24 h, flow cytometry data showed the percentage of apoptotic cells The
experiment was repeated three times and the percentage of apoptotic cells was presented as mean ± SD. **, P < 0.01 vs. IR treatment alone.
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with advanced pancreatic cancer for a few months, the
high rate of recurrence still confused the clinical therapy
[27,28].
As we know, radiation has been widely used for pan-
creatic cancer therapy because it can induce cell death
by damaging cell membranes and DNA [29]. However,
radiation is also able to stimulate some other important
signaling pathways which regulate cell survival, prolifera-
tion and apoptosis [30,31]. Until now, it is unclear about
which signaling pathway plays the key role in the radio-
therapy for unresectable pancreatic cancer. By exploiting
with the patient biopsy samples, we demonstrated that
mTOR expression was significantly up-regulated in clinicalradiotherapy tissues, suggesting that it may contribute to
the clinical radiotherapy resistance. This data provided the
direct in vivo clinical evidence supporting that radiation in-
duced mTOR upregulation might in association with pan-
creatic cancer cell resistance to radiation. From the cell line
data, we also observed mTOR over-expression and over-
activation after radiotherapy. Considering that miRNAs
participated in various physiological and pathological pro-
cesses by directly regulating target genes expression, we
purposely detected various putative miRNAs that may re-
press mTOR and miR-99b was found to be down-regulated
by radiation. Not surprisingly, mTOR was reversely regu-
lated when miR-99b was overexpressed or knocked down
under both basal and radiation conditions. In addition, cell
Figure 7 Inhibition of radiation induced mTOR phosphorylation enhances antitumor efficacy of radiotherapy in vivo. Four groups of Nu/
Nu nude mice (n=10) with PANC-1 xenografts were treated as indicated. After 21 days treatment, the mice were sacrificed and the tumors were
removed. (A) The tumor volumes from the same group mice were presented as mean ± SD and statistically analyzed. *, P < 0.05 and **, P < 0.01
vs. control and #, P < 0.05 and ##, p < 0.01 vs. radiation treatment alone. (B) The xenografts were embedded in paraffin blocks and paraffin
sections were examined by immunohistochemistry using p-mTOR antibody. (C) Apoptosis in tumor tissues was analyzed by TUNEL assay using
Tumor TACSTM In Situ Apoptosis Detection Kit. TUNEL positive cells were counted for every 1000 cells from ten areas of each slide, and three
different slides were analyzed for each sample. Data represents as mean ± SD, **, P < 0.01 vs. IR treatment alone.
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Our results not only provide some new clues for mTOR
upregulation in radiation-treated pancreatic clinical samples
and cell lines, but also demonstrated that miR-99b played
important roles in pancreatic cancer radioresistance and
maybe a candidate therapeutic target for pancreatic cancer.
Considering mTOR was up-regulated by radiation
through miR-99b and mTOR signal pathway plays crit-
ical roles in regulating cancer cell survival, proliferation
and apoptosis, we wonder whether mTOR inhibition
have synergistic effects with radiotherapy. AZD8055, an
mTORC1/C2 dual inhibitor, was employed to inhibit
mTOR activity and block the feedback activation of AKT.
Results demonstrated that AZD8055 treatment signifi-
cantly potentiates the cytotoxic effects of ionizing radi-
ation in human pancreatic cancer cell lines. Additionally,
we also confirmed that the growth inhibition was accom-
panied by a perturbation of cell cycle with the marked re-
duction of cells in S phase and an accumulation in G0/G1phase. Moreover, AZD8055 treatment enhanced radiation
induced cell apoptosis. Intriguingly, these events were
paralleled by suppressing the expression and function of
mTOR, but do not influence the anti-apoptotic family
members such as Bcl-2, Bcl-XL and Mcl-1, suggesting that
AZD8055 and radiation synergistically induced cell apop-
tosis through mTOR related signaling pathways but not
Bcl-2 family in pancreatic cancer cells.
Similar to in vitro results, the growth of pancreatic cancer
xenografts was also inhibited by fractionated radiotherapy
or application of AZD8055 in vivo, and surely combina-
tion of AZD8055 and radiotherapy suppressed growth of
PANC-1 xenografts more effectively than treatment with
either therapy alone. On the whole, inhibition of mTOR
activity by AZD8055 effectively reversed radio-resistance
both in vitro and in vivo. Therefore inhibiting mTOR ac-
tivity by AZD8055 may be an effective way to overcome
radioresistance and potently sensitize pancreatic cancers
to radiation.
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in clinically treated biopsy samples and identify a novel
mechanism related with mTOR upregulation in pancre-
atic cancer cells after radiation therapy. miR-99b reduc-
tion was involved in mTOR upregulation and therefore
affected the radiotherapy sensitivity of pancreatic cancer
cells. Blockade of mTOR by AZD8055 represents a new
therapeutic strategy to overcome radioresistance in pa-
tients with pancreatic cancer.
Conclusions
In conclusion, the results of this study demonstrate the
upregulation of mTOR by radiation via downregulating
miR-99b and provide the first evidence of the regulatory
effects of radiation on mTOR expression and activation.
We propose that mTOR play a critical role in radio-
resistance and its dual inhibitor AZD8055 can be used in
combination with radiation to overcome the radioresis-
tance in pancreatic cancer treatment.
Materials and methods
Materials
AZD8055 was purchased from Selleck Chemicals (Houston,
TX, USA). Antibodies for mTOR, p-mTOR, Akt, p-Akt
(S473), S6 and p-S6 (Ser235/236) were purchased from Cell
Signaling Technology (Beverly, MA). Bcl-2, Bcl-XL and
Mcl-1 antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Tumor TACS™ In Situ Apoptosis Detec-
tion Kit was purchased from Trevigen, Inc. (Gaithersburg,
MD). mTOR shRNA was obtained from Sigma-Aldrich (St.
Louis, MO). All other reagents were obtained from stated
commercial sources.
Biopsies collection of pancreatic cancer patients
Patients with locally advanced pancreatic cancer were di-
agnosed by computed tomography (CT) and MRI imaging,
and all patients received a comprehensive evaluation and
were considered to be unresectable. Eight patients were
treated with Intensity-modulated radiation therapy (IMRT)
at 50 Gy and responses were evaluated via computed tom-
ography. Five patients who have stable disease (SD) or pro-
gressive disease (PD) were resistant to IMRT among total
8 patients. The biopsies were taken by tru-cut needle from
these five radiotherapy resistant patients. None of the sub-
jects received other biotherapy or chemotherapy treat-
ments. The study was approved by the ethics committees
of the First Hospital of Jilin University and the Fourth
Military Medical University. Written informed consents
were also obtained from all subjects before study.
Cell culture and sulforhodamine B assay
Human pancreatic cancer cells PANC-1, Capan-2 and
BxPC-3 purchased from National Rodent Laboratory Ani-
mal Resource (Shanghai, China) were grown as previouslydescribed [32]. Briefly, these cell lines were cultured and
maintained in exponential growth in Dulbecco’s modified
Eagle’s medium (DMEM) containing 100 IU/ml penicillin,
100 μg/ml streptomycin, 20 mM glutamine and 10% heat-
inactivated FCS (Atlanta Biologicals, Lawrenceville, GA)
in a humidified atmosphere of 5% CO2 at 37°C. For sul-
forhodamine B (SRB) assay, the exponential growing
cells were seeded at 6–8 × 103/well in 96-well plates and
cultured overnight. Cells were treated with radiation
alone or combined with AZD8055. AZD8055 was added
to cultured cells and radiation was applied 4 h later in
single doses of 1, 2.5, 5 or 10 Gy. The cells were irradiated
using an X-ray machine (X-RAD 320, Precision X-ray) at
320 kV, 10 mA with a 2-mm aluminum filter, and the dose
rate was 2 Gy/min. Cells were then cultured at 37°C for
48 h and the surviving fractions were determined using
SRB assay as previously described [33,34]. The absorbance
was measured with a spectrophotometer (Bio-Rad Inc) at
510 nm and cell growth inhibition was calculated by using
the equation: cell viability (%) = (At/Ac) × 100%, in which
At and Ac represent the absorbance in treated and control
cultures respectively, as described previously [12].
Cell lysate and Western blot assay
Cells were lysed in ice-cold EBC buffer (50 mM pH 8.0
Tris, 120 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 20 μM sodium
orthovanadate, 1 × Protease Inhibitors, 1 × Phosphatase
Inhibitors) and proteins were quantified and subjected
to SDS-PAGE electrophoresis, followed by protein trans-
fer to nitrocellulose membranes. The membranes were
incubated with the primary and secondary antibodies,
then developed by chemiluminescence [35].
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cells using Trizol (Invitrogen),
1–10 μg of RNA was used to synthesize cDNA with Super-
Script II First-Strand Synthesis System (Invitrogen) or
TaqMan® MicroRNA Reverse Transcription Kit (Applied
Biosystems). Aliquots of the reaction mixture were used
for real-time PCR with Power SYBR Green PCR Master
Mix or with the TaqMan® 2 × Universal PCR Master
Mix. The reaction conditions: 50°C for 20 s, 95°C for
10 min followed by 40 cycles of 95°C for 15 s, 60°C for
1 min. All real-time PCR experiments were performed
in triplicate. A melting curve was obtained to verify the
presence of a single amplicon. The primer sequences
are as described previously [36-38].
Colony formation assay
PANC-1 cells were seeded in 6-well-plates (1000 /well),
and then treated or untreated with radiation and AZD-
8055, alone or in combination. The medium was re-
placed with fresh medium containing the reagent and
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ment, the medium was removed and cell colonies were
stained with crystal violet (0.1% in 20% methanol). Pic-
tures were taken using a digital camera to record the re-
sult as described [9]. To evaluate the colony formation
ability of irradiation-resistant cells, PANC-1 irradiation-
resistant cell line (PANC-1-RR) was firstly generated by
plating PANC-1 cells in 100-mm culture dishes and ir-
radiating with 2 Gy X-ray every three days over a period
of 5 months, for a total dose of 100 Gy, and then colony
formation assay was used as above mentioned [39].
Transfection
PANC-1 cells were suspended in DMEM supplemented
with 10% FBS and seed in 6-well plates (1 × 106/well) and
transfected with miR-99b precursor or inhibitor (Ambion)
with Lipofectamine™ 2000 (Invitrogen) according to the
manufacturer’s instruction. After 48 h of transfection, cells
were treated by radiation at 5 Gy, then harvested and lysed
for Western blot assay [40]. For mTOR interfering, mTOR
shRNA with the sequence of CCGGGCTGTGCTAC
ACTACAAACATCTCGAGATGTTTGTAGTGTAGCAC
AGCTTTTTG was used to transfect PANC-1 cells.
Apoptosis analysis
Annexin V/PI Apoptosis Detection kit (Clontech Labora-
tories) was used for quantification of apoptosis. Cells were
seeded in 6-well plates in the absence or presence of
AZD8055 (500 nM), then radiation was applied 4 h later.
After cultured for 24 h, 0.5-1 × 106 cells were collected
into each tube and gently washed with PBS. Cell pellets
were suspended in 1 × binding buffer and stained with
Annexin V and PI. After incubated for 15 min at RT in
the dark, the apoptosis analysis was carried out using a
FACScan (BD Biosciences) and analyzed using FlowJo
software (Tree Star Inc).
Cell cycle analysis
Cells were synchronized by growing in serum free medium
for 48 h and then released into the cell cycle by adding
10% FBS to the medium. The cells were treated with radi-
ation in the absence or presence of AZD8055 (500 nM)
for 24 h, harvested, fixed with 70% ethanol, and stained
with PI. Data were acquired using flow cytometry and ana-
lyzed using FlowJo software.
Pancreatic cancer xenografts and treatments
Animal experiments were careful to follow the protocols
approved by Jilin University and the Fourth Military
Medical University Institutional Animal Care and Use
Committees. PANC-1 cells (7 × 106) were resuspended in
HBSS and injected subcutaneously into the flank region of
6-week-old female athymic (nu/nu) mice (Shanghai, China).
The tumors were allowed to grow to average volume of200 mm3 prior to initiation of therapy as described [41].
Then mice were assigned randomly to four groups (n =10)
as following: (1) vehicle control (5% DMSO, 100 μl/d p.o.);
(2) 8 Gy fractionated radiotherapy (2 Gy for every three
days); the radiation was performed using the same X-ray
machine with a different filter (1.5 mm aluminum, 0.8 mm
tin, and 0.25 mm copper), at a dose rate of 1 Gy/min; (3)
AZD8055 (20 mg/kg/d), AZD8055 was dissolved in DMSO
and administered by oral gavage (0.1 ml/10 g of body
weight); (4) Combination of AZD8055 (20 mg/kg/d) and
8 Gy (2Gy × 4) fractionated radiotherapy. Tumor volumes
were measured with a caliper every other day and calcu-
lated based on the formula: V = 4/3 × π(length/2 × (width/
2)2). After 21 days treatment, mice were sacrificed and the
tumors were removed and submerged in 10% neutrally
buffered formalin for immunohistochemistry analysis.
Immunohistochemistry
Four-μm thick paraffin sections were deparaffinised,
rehydrated and stained using the R.T.U.Vectastain kit
following the manufacturer’s standard protocol (Vector La-
boratories). The sections were incubated with anti-mTOR
antibody (1:50) overnight at 4°C, then stained with second-
ary antibody. Thereafter, the slides were exposed to DAB
chromogen for 5 min, then hematoxylin counter stained,
dehydrated, and treated with xylene following the approach
as earlier reported [42]. Finally all slides were examined and
representative pictures were taken using an Olympus BX41
microscope.
TUNEL assay
TUNEL staining was performed by using Tumor TACS™
In Situ Apoptosis Detection Kit (Trevigen), the specimens
were deparaffinised and labeled following the procedure
provided by the manufacturer. Finally, DAB staining were
visualized under microscopy [43]. For TUNEL assay, ten
fields were randomly selected from each slide for mea-
surement, the images were analyzed by MetaMorph soft-
ware and presented as a percentage of the total number of
cells [44].
Statistical analysis
Levels of significance were determined by different
methods, two-sided unpaired student’s t-test and one-
factor ANOVA were used in the comparison between
groups [45], and LSD-t tests was used in multiple com-
parisons. Results were considered statistically significant
at P values < 0.05.
Additional file
Additional file 1: Figure S1. mTOR is a target gene of miR-99b. (A)
Sequence alignment of miR-99b with reverse complementary miR-99b
(rcmiR-99b, as the positive control), mTOR, mutant rcmiR-99b (mrcmiR-99b)
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Dual-luciferase reporter vectors were constructed with rcmiR-99b/mrcmiR-99b
and mTOR-3′-UTR/mmTOR-3′-UTR cloned between Not I and Xho I sites in
psiCHECK plasmid and murine macrophage RAW264.7 cells were transfected
with the vectors alone or in the presence of miR-99b precursor or inhibitor.
Vectors containing rcmiR-99b and mrcmiR-99b were used as controls. Renilla
luciferase (RLuc) activity was measured and normalized to Firefly luciferase
(FLuc), and recombinant vectors were normalized to empty vector. *P < 0.05
and **P < 0.01 vs. plasmid alone group. Data are representative of three
experiments.
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